1396 results about "Analgesic effect" patented technology

The analgesic properties of L-tryptophan and 5-HTP can be safely enhanced with the coadministration of salacin. Salacin can be effectively provided in the form of white willow bark along with other ingredients to further enhance the formulation's analgesic effect. As salacin can cause the loss of vitamin C in humans, the formulation advantageously includes a supplemental amount of vitamin C.

Implantable osmotic pump devices and systems include multiple osmotic pumps and/or semipermeable membranes to extend the useful life cycle and functionality of the drug delivery system. Use of an implantable system including multiple implantable osmotic pumps allows different drugs to be administered from the same implanted system. One or more of the semipermeable membranes of the system may be initially sealed by an overlying impermeable membrane upon implantation of the system into the patient. When the patient develops a tolerance to a first drug or to a first dose of the first drug, the impermeable membrane may be breached, to expose the underlying semipermeable membrane to the osmotic pressure of the patient at the implant site. This causes the infusion rate to increase, thereby providing the patient with the needed relief and/or other desired therapeutic effect. In the case of a multiple pump system, breaching an impermeable membrane may cause the infusion of a second drug. The second drug may potentiate a therapeutic effect (such as an analgesic effect) of the first drug, as is the case with Sufentanil and Clonidine.

PCT No. PCT/DK97/00101 Sec. 371 Date Jun. 22, 1998 Sec. 102(e) Date Jun. 22, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/32573 PCT Pub. Date Sep. 12, 1997An oral pharmaceutical modified release multiple-units composition for the administration of an analgesically effective amount of an opoid. The composition comprises at least two fractions wherein individual units containing an opoid are coated with a sustained release coating. A first fraction is adapted to relatively fast release while a second fraction is adapted to a delayed release. Such compositions make possible to obtain both a relatively fast onset of the analgesic effect and the maintenance of analgesically active plasma concentration for a relatively long period of time. The invention further relates to a process for the preparation of a composition according to the invention.

Compounds of general formula (I)are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an analgesic effect on a disease model animal of neurogenic pain which is a non-inflammatory pain. Therefore, the analgesic agent is useful as a pharmaceutical agent for the treatment of a non-inflammatory pain disease such as a neurogenic pain disease, e.g. trigeminal neuralgia, postherpetic neuralgia, entrapment neuropathy, complex regional pain syndrome, diabetic neuropathy, traumatic neuropathy, phantom limb pain, central pain after spinal cord injury or stroke, and neuropathy caused by pharmacotherapy or radiation therapy, or the like.

Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.

The invention relates to a 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate, relative synthesis method and application, belonging to the technical field of chemical pharmacy, which comprises that adds acid into diclofenac salt to acidify the salt into diclofenac, reacts diclofenac with methanol, or adds acid into diclofenac salt to acidify the salt into diclofenac, to be reacted with chloracetyl chloride to obtain 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate. The inventive drug has significant anti-inflammatory and analgesic effects.

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention discloses throat nourishing health-care type electronic cigarette liquid, which is used for producing electronic cigarettes, can meet the requirement of smoking addiction, contributes to smoke absorbing and throat nourishing, protects the throat of a human body and maintains health. The electronic cigarette liquid mainly comprises the following components in percentage by weight: 2 to 6 percent of plant cigarette substituting agent, 48 to 55 percent of propylene glycol, 25 to 35 percent of pure water, 4 to 6 percent of tobacco flavor, 0.25 to 1.2 percent of stabilizer, 4 to 9 percent of thickening agent and 3 to 6 percent of Chinese medicinal component, wherein the Chinese medicinal component comprises 3 to 5 types of watermelon frost, peppermint oil, menthol, blumea aromatria, eucalyptus oil and star anise oil according to an equal proportion. The electronic cigarette liquid has the effects of promoting secretion and nourishing throat, clearing sound and eliminating phlegm, and reducing swelling and relieving pain during the enjoyment of smoking, can prevent and treat throat sore, hoarseness, canker sore, stomatitis and gum swelling and pain, and has good curative effect on throat diseases such as dryness, swelling and pain of the throat accompanied by the hoarseness.

PCT No. PCT/SE96/01635 Sec. 371 Date Apr. 24, 1997 Sec. 102(e) Date Apr. 24, 1997 PCT Filed Dec. 11, 1996 PCT Pub. No. WO97/23466 PCT Pub. Date Jul. 3, 1997Compounds of the formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.

The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect by the administration of the paracetamol formulation.

The present invention belongs to the field of Chinese medicine technology, and provides one kind of plaster for treating arthralgia. The plaster is prepared with dragon's blood, curcuma, dahurian angelica root, Chinese ephedra, pubescent angelica root, and other Chinese medicinal materials. Clinical application for years shows that the plaster has high curative effect, no toxic side effect, and other advantages, and can heal arthralgia radically.

The present invention discloses a slow-released medicine preparation with the function of promoting blood circulation, removing staiss, removing obstruction in the channels to relieve pain. In particular it is a slow-released medicine preparation containing breviscapine. The described breviscapine is scutellarin or 4-hydroxy ba icalein-7-O-beta-D-pyrangluconate methyl ester.

A polymethacrylate or other bone cement composition having analgesic properties is described. Bone cements containing up to 5% by weight of a local anaesthetic agent, such as lidocaine, have been demonstrated to elute sufficient lidocaine to provide an analgesic effect in vivo.

A dressing for promoting healing and pain relief of the body of a living organism having a pathologic condition has at least one layer of conductive material having a resistance no greater than 1000 Ω/cm². When placed proximate a portion of the body of the living organism suffering from the pathologic condition, the dressing alters the electrodynamic processes occurring in conjunction with said pathologic condition to promote healing and pain relief in the living organism. When used as a wound dressing, the conductive material is placed in contact with tissue around the periphery of the wound and with the wound, lowering the electrical potential and resistance of the wound and increasing the wound current. In an exemplary embodiment, the conductive material is a multi-ply nylon fabric plated with silver by an autocatalytic electroless plating process and with the plies in electrical continuity. The dressing provides an antimicrobial and analgesic effect. The dressing may be provided for numerous applications and may include other layers such as an absorbent layer, a semi-permeable layer and additional layer of conductor material. Multilaminate embodiments of the present invention exhibit conductive material concentration gradients and, potentially, a capacitive effect when sequential conductor layers are insulated by intervening layers.

A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration

The present invention is concerned with an anti-inflammation analgesic preparation which contains a specific 3-0-substituted ascorbic acid as an active ingredient, shows excellent anti-inflammation analgesic effects and is excellent in shelf life, safety to a skin and endermic absorptivity of the active ingredient.

A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium glycinate, potassium glycinate and tribasic sodium and potassium phosphates and mixtures thereof, and reacting the ibuprofen and the first base in essentially dry state. The obtainable granulate and the pharmaceutical compositions and dosage forms that may be produced therefrom are distinguished by their high solubility and rapid disintegration and dissolution in aqueous media, by their good flow properties and compressibility, by rapidly achieving onset of analgesic effect.